Should Politicians Fix Sovaldi's Price?

Gilead (NASDAQ: GILD) has become the whipping boy du jour for the forthcoming Obamacare-driven cost explosion in government and private health spending. Apparently, everything was going swimmingly until Gilead – right out the blue! – dropped a cure for Hepatitis C on the market and threw everyone’s spending projections into a tizzy.

Politicians and the health-insurance industry have embarked on a high-profile campaign to shame Gilead for the price of its new wonder-drug, Sovaldi, which can add up to $84,000 for a course of treatment. If successful, this campaign will have terrible long-term consequences for medical innovation

Read the entire column at Forbes.